Evelo Biosciences, Inc.
Evelo Biosciences, Inc. (EVLO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EVLO · as of Sep 30, 2023
Ownership Breakdown
1
Institutional Holders
$88,502
Total Inst. Value
▲ $15,127 vs Q2
18.98M
Shares Outstanding
freeFloat 99.54%
22,577
13F Shares Held
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EVLO largest shareholders · institutional ownership
Q3 2023 · SEC 13F
Showing top 1 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MAYO CLINIC pharmaceutical preparations | 22.6K | 40.47% | 40.47% | $88.50M | Nov 14, 2023 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2023 vs prior quarter
Q3 2023
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares0
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+0
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EVLO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
14
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bodmer Mark CSO, President of R&D | Nov 8, 2023 | Sale | 3,163 | $0.33 | $1.0K | 25.7K | Form 4 ↗ |
McHale Duncan Chief Medical Officer | Nov 8, 2023 | Sale | 3,103 | $0.33 | $1.0K | 17.0K | Form 4 ↗ |
GILL SIMBA President & CEO | Nov 8, 2023 | Sale | 172 | $0.33 | $56.76 | 17.8K | Form 4 ↗ |
Thorell Marella Chief Financial Officer | Nov 8, 2023 | Sale | 1,811 | $0.33 | $597.63 | 22.3K | Form 4 ↗ |
Bodmer Mark CSO, President of R&D | Nov 2, 2023 | Sale | 6,854 | $0.33 | $2.3K | 22.3K | Form 4 ↗ |
McHale Duncan Chief Medical Officer | Nov 2, 2023 | Sale | 6,854 | $0.33 | $2.3K | 13.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Evelo Biosciences, Inc. (EVLO) is primarily owned by institutional investors, who hold approximately 0.1% of total shares outstanding. Company insiders own approximately 0.46%, while retail and public investors account for the remaining 99.42%.
The largest institutional shareholder of Evelo Biosciences, Inc. is MAYO CLINIC, holding approximately 22,577 shares — equal to 40.47% of outstanding shares — as of September 30, 2023.
A total of 1 institutional investors currently hold EVLO stock, with a combined institutional value of approximately $88,502 as of the most recent 13F filing period.
Frequently asked questions
EVLO ownershipEvelo Biosciences, Inc. (EVLO) is primarily owned by institutional investors, who hold approximately 0.1% of shares. The largest shareholder is MAYO CLINIC with a 40.47% stake. Company insiders hold 0.46%. Data sourced from SEC Form 13F as of September 30, 2023.